Addressing Cancer Care Disparities in Europe: Insights from the 2025 Comparator Report

By João L. Carapinha

March 27, 2025

The “Comparator Report on Cancer in Europe 2025” analyzes the landscape of cancer care across Europe. It highlights cancer care disparities persisting in different European regions and cancer types. While advances in treatment exist, many patients still struggle to access timely and effective care. Molecular diagnostics are also key for precision oncology but vary in access. Lower-income regions lack complex assays, worsening disparities in care quality.

Cancer is the world’s second-leading cause of death, with nearly 10 million deaths in 2020. The OECD’s “Health at a Glance 2023” stresses the need for better prevention and care strategies in Europe.

Rising Incidence and Reimbursement Speed

Cancer incidence in Europe rose by 58% from 1995 to 2022, reaching 3.2 million new cases yearly. Mortality rates have stabilized at 1.3-1.4 million deaths since 2008, reflecting complex factors influencing outcomes. Direct cancer treatment costs doubled from €62 billion in 1995 to €146 billion in 2023. Medicine costs now exceed 40% of total expenses, worsening access for disadvantaged groups.

Wealthier Western European countries quickly reimburse EMA-approved drugs. Meanwhile, Central and Eastern Europe face delays and restricted coverage. These cancer care disparities demand equitable policies to bridge gaps.

Implications for Health Economics and Market Access

Health Economics and Outcomes Research (HEOR) can improve cancer care access. It provides evidence to optimize resource allocation and cost-effectiveness. Frameworks like the ISPOR Value Flower could integrate societal impacts into HTA. Performance-based MEAs and multi-speed HTA processes may prioritize promising drugs while monitoring uncertain ones.

More public funding is needed for treatment optimization studies and data infrastructure. Evolving HTA methodologies should adopt a societal perspective to ensure fair access to innovative treatments.

These findings highlight the urgency of addressing cancer care disparities. HEOR can enhance equity and efficiency in healthcare. For deeper insights, explore the full report.

 

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.